The 42 on the side of the car is a nod to the newly-released Norvo Nordisk diabetes drug Tresiba, which Kimball, a Type I diabetic, has been taking since the first of the year.
"The 100th running of the Indianapolis 500 will be the highlight of this year's season and it gives me a great opportunity to honor the diabetes community and help inspire those people living with or affected by diabetes,” Kimball said. “I am honored to represent Novo Nordisk and Chip Ganassi Racing and to share my story with the diabetes community."
Once a patient has been taking the drug for at least eight days, it lasts in the body up to 42 hours, something that has benefitted Kimball greatly already this season.
“With all the time zones we go through, racing in Phoenix, racing in Long Beach, back-to-back Long Beach to Barber and back to Indianapolis in the middle, those were three time zones within the span of about five days,” Kimball said. “And the fact that when I get up in the morning, whether that’s 6 am like it was on race day or 10 am like it was yesterday when I was lazy and slept in, I can get up and take my Tresiba at that point and not have to really set my schedule around my diabetes management.”
Ganassi teammate Kyle Larson, who drove the #42 Target Chevrolet in Sunday’s Sprint Cup race at Dover International Speedway and finished second, joined Kimball and team owner Chip Ganassi for the announcement.
"All of us who race for Chip really are one team and it's really cool to share the No. 42 with Charlie, especially for this historic race,” Larson said. “He is a strong and popular advocate for the diabetes community and I can't wait to see him and the No. 42 in this year's Indianapolis 500."
Kimball and Ganassi’s relationship began long before they became owner and driver. Kimball’s father helped design the car Ganassi drove for in 1983, Ganassi’s best ever Indy 500 finish.
"It's been great to see Novo Nordisk use their racing partnership with Chip Ganassi Racing Teams to launch one of their brands, and I love that we're strengthening our 'one team' mantra with the sharing of the number 42 across different series,” Ganassi said. “The number 83 is obviously very meaningful to both Charlie and myself, but the number 42 is also just as meaningful with this product and the diabetes community. Charlie had a great run last year at the 500, so hopefully the 42 will bring Novo Nordisk Chip Ganassi Racing and Charlie their first Indianapolis 500 victory."